CardioFocus has raised $13 million in a new round of mixed financing, according to an SEC filing posted this week.
Money in the round comes from a single unknown investor, according to the filing, with the first sale noted as having occurred on April 4.
The Marlborough, Mass.-based company said that $2.6 million from the offering will go towards sales commissions and finders fees, according to the filing.
CardioFocus is seeking an additional $8 million before closing the offering, bringing the total it hopes to raise up to $21 million.
In February, CardioFocus said that it launched a clinical trial for the latest iteration of its HeartLight direct-visualization ablation device for treating atrial fibrillation.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.